Loading
Life sciences · Journal article
Frontiers in Genetics · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Artificial Intelligence (AI) is revolutionizing gene therapy from an empirical and iterative process to a predictive, data-driven and increasingly intelligent therapeutic development approach. This review covers the application of AI extensively throughout the gene therapy development process, from target therapeutic discovery, identification of disease genes, variant interpretation, integration of multi-omics data, optimization of CRISPR, engineering of the vector, prediction of immunogenicity, manufacturing, and clinical development and post-marketing surveillance. The role of machine learning, deep learning, foundation models, generative AI and digital twins for advancing therapeutic design, boosting vector performance, manufacturing optimization, patient stratification and enabling precision medicine is discussed. Lastly, we provide directions for future research and highlight the need for close multidisciplinary cooperation between computational scientists, biologists, clinicians, industry, and regulatory agencies to facilitate the development of safe, effective and personalized genetic medicines responsibly.